Realising safer tuberculosis treatment with novel antibiotics

Publication date: Jul 10, 2025

The World Health Organisation (WHO) recommended it as a standard six-month treatment for multidrug-resistant tuberculosis, the researchers highlighted. However, despite its effectiveness, linezolid is simply too toxic for many patients. On the other hand, delpazolid improved the effectiveness of the combination therapy with bedaquiline, delamanid, and moxifloxacin. A once-daily 1200mg dose achieved the desired drug levels for maximum efficacy.

Concepts	Keywords
1200mg	Antibiotics
Antibiotic	Bedaquiline
July	Delpazolid
Pulmonary	Drug
Therapyspecifically	Drugs
	Linezolid
	Moxifloxacin
	Options
	Patients
	Requiring
	Resistant
	Safer
	Sutezolid
	Treatment
	Tuberculosis

Semantics

Type	Source	Name
disease	MESH	tuberculosis
pathway	KEGG	Tuberculosis
disease	IDO	intervention
disease	MESH	drug-resistant tuberculosis
disease	MESH	pulmonary tuberculosis
drug	DRUGBANK	Delamanid
disease	MESH	Infectious Diseases
drug	DRUGBANK	Moxifloxacin
drug	DRUGBANK	Pretomanid
drug	DRUGBANK	Bedaquiline
drug	DRUGBANK	Linezolid
drug	DRUGBANK	Sutezolid
disease	IDO	role